Antiviral Therapy in Mollaret Meningitis
Antiviral therapy is NOT indicated for Mollaret meningitis, either for acute episodes or for prophylaxis against recurrence. The highest-quality evidence demonstrates that oral valaciclovir does not reduce recurrent HSV-2 meningitis and may paradoxically increase relapse rates after discontinuation 1.
Acute Episode Management
Treatment should be supportive only—analgesia and intravenous fluids as needed 1, 2.
- While some clinicians empirically treat acute episodes with aciclovir or valaciclovir, there is no evidence supporting efficacy for either HSV or VZV meningitis 1.
- The potential risks from drug side effects (including nephrotoxicity in up to 20% of patients) and unnecessarily prolonged hospitalization outweigh any theoretical benefit 1, 3.
- If antibiotics were started empirically, they should be discontinued once viral etiology is confirmed by CSF PCR 1, 2.
- Priority should be given to expediting hospital discharge once the diagnosis is established 1.
Prophylactic Therapy
Prophylactic antiviral therapy is explicitly not recommended based on Level I evidence 2.
- A placebo-controlled trial demonstrated that oral valaciclovir failed to reduce recurrences of HSV-2 meningitis 1.
- Patients who received valaciclovir actually tended to have greater relapse rates once the trial stopped 1.
- The lack of efficacy was attributed to inadequate drug levels in the CSF, though aciclovir concentrations were not directly measured 1.
- While higher doses might theoretically improve outcomes, no studies have evaluated this approach 1.
Diagnostic Confirmation
Before withholding antiviral therapy, confirm the diagnosis appropriately:
- CSF PCR for HSV-2 is the gold standard for confirming viral etiology 1, 2.
- Most laboratories test for enterovirus, HSV-1, HSV-2, and VZV 1, 2.
- HSV-2 is identified in the majority of cases where a virus is isolated 2.
- No cause is found in 30-50% of patients with presumed viral meningitis 1.
Critical Exception: Encephalitis
If any encephalitic features develop, immediately initiate intravenous aciclovir for presumed HSV encephalitis 1, 3, 2.
Encephalitic features requiring immediate treatment include:
- Changes in personality, behavior, or cognition 1, 2
- Altered conscious level 1
- Reduced Glasgow Coma Score 3
In these cases, follow the British Infection Association/Association of British Neurologists guidelines on encephalitis management, which recommend aciclovir 10 mg/kg three times daily for 14-21 days 3.
Clinical Pitfalls to Avoid
- Do not confuse meningitis with encephalitis: Mollaret meningitis patients typically have normal consciousness; altered mental status suggests an alternative diagnosis requiring different management 1, 2.
- Do not prescribe prophylactic antivirals: Despite their efficacy in reducing genital HSV-2 transmission and recurrences, these agents do not prevent recurrent meningitis 1.
- Do not assume genital herpes history: Most patients with HSV-2 Mollaret meningitis do not have concurrent genital ulcers or known history of genital disease 1, 2.